Kura Oncology’s (KURA) Overweight Rating Reaffirmed at Cantor Fitzgerald

Kura Oncology (NASDAQ:KURA)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, Benzinga reports.

Other analysts also recently issued research reports about the company. UBS Group assumed coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Wednesday. Finally, JMP Securities restated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $28.83.

Kura Oncology Stock Performance

Shares of KURA traded up $0.71 during mid-day trading on Wednesday, hitting $18.23. The stock had a trading volume of 33,337 shares, compared to its average volume of 888,090. The company has a market cap of $1.40 billion, a PE ratio of -8.17 and a beta of 0.86. The company’s fifty day simple moving average is $18.95 and its two-hundred day simple moving average is $20.02. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $8.17 and a fifty-two week high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. During the same period last year, the business posted ($0.53) EPS. The company’s revenue was up .0% compared to the same quarter last year. On average, equities analysts expect that Kura Oncology will post -2.46 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of KURA. Avoro Capital Advisors LLC boosted its stake in shares of Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after purchasing an additional 577,732 shares during the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of Kura Oncology by 281.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock valued at $15,581,000 after purchasing an additional 538,957 shares during the last quarter. Sofinnova Investments Inc. boosted its stake in shares of Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares during the last quarter. Finally, Armistice Capital LLC boosted its stake in shares of Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after purchasing an additional 302,000 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.